Narcolepsy: Recognizing the Signals, Reducing Diagnostic Delay, and Improving Patient Outcomes

Narcolepsy most commonly presents in individuals aged 10 to 30 years.[1] It is considered a rare disease, but narcolepsy is widely assumed to be underdiagnosed and it is thus considered a rare disease. However, the disorder is widely assumed to be underdiagnosed: A survey of 16,000 adult Americans (mean age, 45.6 yr) revealed that 0.9% experienced “sudden and irresistible sleep” daily.[5] The same survey found that sudden and irresistible sleep was experienced daily by at least the same percentage of adults 55 years or older compared with those younger than 35.[5] 

The incidence of narcolepsy has been estimated to be 0.7 to 2.6 per 100,000 person-years. The prevalence of type 1 disease (i.e., with cataplexy) was estimated to be 12.6 per 100,000 individuals; type 2 narcolepsy (i.e., without cataplexy) was estimated to be 25.1 per 100,000 people. This equates to a US patient population of approximately 126,000. The incidence per year was 2.6 per 100,000 individuals.[5] 

Narcolepsy does not predominate in either gender. However, the general population survey revealed that women were significantly more likely than men to report moderate-to-severe daytime sleepiness (P < .0001).[5]

Patients with narcolepsy experience a fundamental instability of the sleep–wake cycle, which is caused by the loss of hypocretin-/orexin-producing neurons. Hypocretin-1 (a term used interchangeably with “orexin-A”) is a neuropeptide neurotransmitter that is produced in the hypothalamus. Hypocretin mediates a person’s levels of appetite, arousal, and wakefulness.[4,6,7] 

Crucially, in terms of narcolepsy, appropriate levels of hypocretin in the cerebral spinal fluid regulates alertness, and it ensures normal sleep-REM cycles. A deficiency in hypocretin-1–producing neurons is the specific cause of narcolepsy.[4] 

The reasons why a person would experience a deficit in hypocretin levels are not yet known, but an autoimmune response is suspected, involving the HLA-DQB1*0602 allele. This allele is carried by nearly all patients (98%) with narcolepsy.[2-4] Research has shown that hypocretin-producing neurons are activated by glutamate, and they are inhibited by dopamine, noradrenaline, and serotonin.[6] A link has not yet been established between this gene variant and hypocretin-producing neuron function.

Although EDS is the most common and earliest symptom of narcolepsy (and it is not affected by the sleep quality of the night previous to an episode), several other symptoms of narcolepsy are notable.[4] 

Cataplexy, which is a hallmark of narcolepsy type 1, refers to a sudden loss of muscle tone, muscle weakness, and an inability to control voluntary movement. Episodes of cataplexy may involve a range of manifestations, from the sudden drooping of a patient’s eyelids to a dramatic fall or collapse to the floor without loss of consciousness. These episodes may last from seconds to a few moments, and they are often triggered by intense emotions (e.g., being angry, laughing, or being surprised or frightened).[2,4] Cateplexy, it should be noted, cannot be easily induced, and thus symptom descriptions are heavily reliant on patient reporting of episodes. It is therefore critical that, during the initial office visit, physicians ask the patient with EDS about a history of cataplexy. 

Patients complain of fragmented or disrupted nighttime sleep (up to 95% of patients), despite their considerable level of daytime fatigue. In general, they report poor overall sleep quality.[3]

Sleep paralysis occurs in up to 50% of patients. It is described as a transient inability to speak or move while falling asleep or upon awakening.[4] 

Hallucinations, with vivid, dream-like experiences, occurring either upon falling asleep or during awakening, are reported by 33% to 80% of patients with type 1 narcolepsy.[4] Both these hallucinations and the sleep paralysis are thought to be “symptoms of dissociation between elements of REM sleep and wakefulness.”[3]

Symptom presentation can vary widely and include REM sleep behavior disorder, periodic limb movements, automatic behavior without conscious awareness, and compulsive-eating disorders, particularly in pediatric populations.[4]

Initial diagnosis or suspicion of type 1 narcolepsy in a patient with sleep disorders should rely on criteria from the International Classification of Sleep Disorders, Third Edition (ICSD-3) and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (Table). As noted, the physician may have to actively ask the patient or caregiver about any episodes of cataplexy, sleep paralysis, and hallucinations that may have occurred. The provider should employ a detailed sleep history, the use of sleep diaries, and actigraphy.[4,8] Confirmatory tests would include polysomnography and multiple sleep latency testing.  

A recent study of 137 Korean patients[9] found the mean time from symptom presentation to diagnosis was 10.3 years: The patients’ mean ages at the onset of symptoms and diagnosis were 18.2 years and 28.3 years, respectively. Another study found that, in France, patients with type 1 narcolepsy had a median diagnostic delay of 4 years (and becoming briefer over the past decades).[10] 

Patients may not recognize their sleep dysfunction as a disorder but as normal fatigue, and patients’ own self-perception and embarrassment may delay their initial visit to a healthcare provider.[9,11] Partly because of the heterogeneity of symptoms, providers may misdiagnose narcolepsy as depression, attention-deficit/hyperactivity disorder, or other sleep disorders—highlighting the need for heightened clinical suspicion. The absence or lack of reporting of cataplexy may contribute further to this diagnostic delay.[9] Providers’ low index of suspicion may further contribute to diagnostic delay.[4] Another important aspect is the patients’ potentially limited access to sleep-study testing. This may relate to geographic distance to services or lack of insurance coverage.[12] 

During this long gap between symptom onset and diagnosis, young patients may experience accumulating psychosocial damage and academic underachievement. Older patients may suffer poor work productivity, and professional setback or nonadvancement.[9,12]

Narcolepsy rarely resolves on its own and remains an issue throughout adulthood.[1] It affects nearly every part of the patient’s life experience. The disorder can impact academic performance and occupational productivity, including the ability to operate a vehicle; it is also associated with a greater risk of workplace accidents.[1,13] Patients with type 1 narcolepsy are somewhat reluctant to interact socially, and children may be ostracized (because of cataplexy episodes in school or at play). 

In a study of US National Health and Wellness Survey data from 2021 and 2023, patients with narcolepsy demonstrated several socioeconomic disadvantages: They were less likely to receive a college degree (45% vs 52%, respectively; P < .05), less likely to have full-time employment (36% vs 46%, respectively; P < .001), three times more likely to receive disability (10% vs 3%, respectively; P < .001), and twice as likely to earn < $25,000 annual income (22% vs 12%, respectively; P < .001).[13] 

The social, economic, and clinical factors contribute to significantly higher rates of anxiety (any form of anxiety, generalized, or social anxiety), panic disorder, and depression (P < .001) compared with individuals without narcolepsy.[1,11,14]

A retrospective survey revealed that narcolepsy was associated with a significantly higher risk of cardiovascular disease (hazard ratio, 1.89) and major adverse cardiovascular events (hazard ratio, 1.95), independent of the use of stimulant therapy.[15] However, researchers from Taiwan found that although crude all-cause mortality in patients with narcolepsy was higher than those without (44.3 vs. 38.1 per 10,000 person-years, respectively), the hazard ratios for mortality from natural causes and accidents or suicides were not significantly higher than in the general population.[14]

Current Treatment. Available medical therapies seek to address the symptoms of narcolepsy and improve function, not correct the underlying loss of hypocretin-producing neurons.[3,4] Therefore, the five drugs approved for the treatment of narcolepsy by the US Food and Drug Administration or the European Medicines Agency are not considered disease-modifying agents. They include:[3,7] 

• The psychostimulants methylphenidate/amphetamines, modafinil/armodafinil, solriamfetol
• The GABA B-receptor–agonist sodium oxybate 
• The histamine H3-receptor–agonist pitolisant 

These agents are used to promote wakefulness (the stimulants), target REM dysregulation and cataplexy (sodium oxybate), and reduce hallucinations as well as overall EDS (pitolisant).[3]

These FDA-approved pharmacotherapies (none are indicated for use in children < 6 yr) may offer alleviation of daytime sleepiness symptoms and cataplexy but have demonstrated considerable side effects (e.g., headaches, nausea, and mood swings). Some effective therapies, such as sodium oxybate, have difficult dosing schedules, challenging patient adherence.[4] Overall, narcolepsy treatments are associated with low adherence and persistence.[3,4]

Furthermore, pharmacologic treatment of the disorder’s psychiatric comorbidities may interfere with the prescribed narcolepsy therapy. For example, common drugs for depression have the potential for interactions with narcolepsy medications, or they may directly and adversely affect a patients’ sleep patterns, complicating the patient’s clinical status.[4]

Emerging Treatments. Research in narcolepsy pharmacotherapy is focused on targeting the orexin-2 receptors, which should result in significant disease-modifying effects.[3,4] Three investigational orexin-2 receptor agonists may address the essential issue in narcolepsy—the loss of orexin-producing neurons. One agent, oveporexton, is awaiting an FDA-approval decision,[16] and another, alixorexton, has entered phase 3 clinical trials.[17] The third agent, ORX750, is the subject of a phase 2 trial at this time.[18]

Key to improving patient quality of life, clinical status, and social/occupational factors, and reducing the general burden of narcolepsy, is early diagnosis and appropriate referral to a physician-led team of caregivers. The extended delay in diagnosis is driven by the heterogeneity of symptoms and limited physician awareness of the key signs. For example, physicians should be educated in the need to prompt patients about any history of cataplexy. Misdiagnosis as anxiety and depression (rather than recognition as comorbidities) or even schizophrenia can cause years of patient suffering.[4]

Although currently available pharmacologic therapy can be effective for addressing specific symptoms of narcolepsy and cataplexy, it should be accompanied by behavioral approaches, including stringent sleep hygiene and a schedule of prescribed daytime naps.

Narcolepsy Network

Wake Up Narcolepsy

Day4NAPS

People With Narcolepsy 4 People With Narcolepsy

1. Flores NM, Villa KF, Black J, et al. The humanistic and economic burden of narcolepsy. J Clin Sleep Med. 2016;12:401-407. http://dx.doi.org/10.5664/jcsm.5594.
2. Dauviliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369:499-511. 
3. Biscarini F, Barateau L, Pizza F, et al. Present and future of central disorders of hypersomnolence. J Sleep Res. 2025;34:e70118. https://doi.org/10.1111/jsr.70118.
4. Hastings NE, El Abdi K, Bibi F, et al. Narcolepsy: Pathophysiology, diagnosis, management, and future directions, a narrative review. Brain Behav. 2025;15:e71116. https://doi.org/10.1002/brb3.71116. 
5. Ohayon MM, Duhoux S, Grieco J, et al. Prevalence and incidence of narcolepsy symptoms in the US general population. Sleep Medicine: X. 2023;6:100095. https://doi.org/10.1016/j.sleepx.2023.100095.
6. Inutsuka A, Yamanaka A. The regulation of sleep and wakefulness by the hypothalamic neuropeptide orexin/hypocretin. Nagoya J Med Sci 2013;75:29-36.
7. Yan Z, Li J, Yu Y, et al. Comparative efficacy of new wake-promoting agents for narcolepsy—a network meta-analysis. BMC Neurology. 2025;25:466. https://doi.org/10.1186/s12883-025-04328-9.
8. Ruoff C, Rye D. The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: Clinical relevance and practicality. Curr Med Res Opin. 2016;32:1611-1622. https://doi.org/10.1080/03007995.2016.1208643. 
9. Jung YJ, Ji K-H, Kim D, et al. Factors associated with diagnostic delay in narcolepsy: Real-world data from a Korean multicenter study. Sleep Med. 2025;133:106646. https://doi.org/10.1016/j.sleep.2025.106646
10. Zhang Z, Barateau L, Beziat S, et al. Age at onset and delays in diagnosis of central disorders of hypersomnolence over the past 30 years. J Sleep Res. 2026;35:e70170. https://doi.org/10.1111/jsr.70170.
11. Hlodak J, Madascova Geckova A, Dankulincova Veselska Z, et al. ‘It’s hard to feel this way every single day’: Patients’ perspectives on the emotional burden of narcolepsy. Front Psychol. 2025;16:1611500. https://doi.org/10.3389/fpsyg.2025.1611500.
12. Hoque R, DelRosso LM. Disparities in diagnosis of and management of narcolepsy and idiopathic hypersomnia. Sleep Med Clin. 2026;21(1):119-125. https://doi.org/10.1016/j.jsmc.2025.10.013.
13. Doane M, Maski K, Cambron-Mellott J, et al. The economic burden of narcolepsy: Matched analysis of US National Health and Wellness Survey data (abstract 806). Sleep 2025;48(suppl 1): A349-A350. 
14. Hsu C-W, Yang Y-S, Chen Y-CB, et al. All-cause and cause-specific mortality among patients with narcolepsy. JAMA Network Open. 2025;8(10):e2536771. https://doi.org/10.1001/jamanetworkopen.2025.36771.
15. Riaz M, Bhattachargee, Lo-Cignanic W, et al. Narcolepsy and risk of cardiovascular outcomes beyond stimulant use. Sleep. 2025;48: zsaf197. https://doi.org/10.1093/sleep/zsaf197.
16. U.S. Food and Drug Administration accepts new drug application and grants priority review for Takeda’s oveporexton (TAK-861) as a potential first-in-class therapy for narcolepsy type 1 (press release). Takeda. February 10, 2026. Accessed March 27, 2026. https://www.takeda.com/newsroom/newsreleases/2026/fda-accepts-nda-priority-review-oveporexton-narcolepsy-type-1/.
17. A study to evaluate the efficacy and safety of ALKS 2680 in adults with narcolepsy type 1 (Brilliance NT1). ClinicalTrials.gov. March 9, 2026. Accessed March 27, 2026. https://clinicaltrials.gov/study/NCT07455383?intr=Alixorexton&viewType=Card&rank=1.
18. A study of ORX750 in participants with narcolepsy and idiopathic hypersomnia (CRYSTAL-1). ClinicalTrials.gov. October 29, 2025. Accessed March 27, 2026. https://clinicaltrials.gov/study/NCT06752668?intr=ORX750&viewType=Card&rank=2.